Antithrombogenic modification of small-diameter microfibrous vascular grafts.
OBJECTIVE
To develop small-diameter vascular grafts with a microstructure similar to native matrix fibers and with chemically modified microfibers to prevent thrombosis.


RESULTS
Microfibrous vascular grafts (1-mm internal diameter) were fabricated by electrospinning, and hirudin was conjugated to the poly (L-lactic acid) microfibers through an intermediate linker of poly(ethylene glycol). The modified microfibrous vascular grafts were able to reduce platelet adhesion/aggregation onto microfibrous scaffolds, and immobilized hirudin suppressed thrombin activity that may interact with the scaffolds. This 2-pronged approach to modify microfibrous vascular graft showed significantly improved patency (from 50% to 83%) and facilitated endothelialization, and the microfibrous structure of the vascular grafts allowed efficient graft remodeling and integration, with the improvement of mechanical property (elastic modulus) from 3.5 to 11.1 MPa after 6 months of implantation.


CONCLUSIONS
Microfibrous vascular grafts with antithrombogenic microfibers can be used as small-diameter grafts, with excellent patency and remodeling capability.
Hashi
Craig K
CK
University of California, San Francisco, CA, USA.
Derugin
Nikita
N
Janairo
Randall Raphael R
RR
Lee
Randall
R
Schultz
David
D
Lotz
Jeffrey
J
Li
Song
S
D000818:Animals; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D055119:Elastic Modulus; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D006629:Hirudins / Q000008:administration & dosage*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D008422:Materials Testing; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011091:Polyesters; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D011474:Prosthesis Design; D051381:Rats; D017207:Rats, Sprague-Dawley; D013917:Thrombin / Q000378:metabolism; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors; D014654:Vascular Patency / Q000187:drug effects
D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents; D006629:Hirudins; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; D011092:Polyethylene Glycols; C033616:poly(lactide); D013917:Thrombin
Nano Lett. 2007 Jul;7(7):2122-8
17567179
Biomaterials. 1997 May;18(10):755-65
9158859
J Thorac Cardiovasc Surg. 1987 May;93(5):695-707
3573782
Adv Drug Deliv Rev. 2007 Dec 10;59(14):1392-412
17884240
Biomaterials. 1996 Jan;17(2):115-24
8624388
FASEB J. 2008 Jun;22(6):1635-48
18199698
Biomaterials. 2008 Aug;29(22):3213-20
18455787
Ann Surg. 2008 Sep;248(3):370-7
18791357
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11915-20
17615237
Circ Res. 2006 Jan 6;98(1):25-35
16397155
Biomaterials. 2006 Mar;27(7):1088-94
16131465
Nat Biotechnol. 1999 Nov;17(11):1083-6
10545913
Annu Rev Biomed Eng. 2001;3:225-43
11447063
Am J Pathol. 1986 May;123(2):220-30
3706490
Nano Lett. 2006 Mar;6(3):537-42
16522058
Cell Transplant. 1996 Jul-Aug;5(4):465-73
8800514
Biomaterials. 2007 Feb;28(6):1191-7
17087991
Tissue Eng. 2005 Sep-Oct;11(9-10):1574-88
16259611
J Biomater Sci Polym Ed. 2008;19(5):653-64
18419943
Biomaterials. 2008 Mar;29(7):825-33
18035412
Nat Med. 2006 Mar;12(3):361-5
16491087
Front Biosci. 2004 May 01;9:1422-32
14977557
Eur J Vasc Endovasc Surg. 2006 Oct;32(4):418-24
16682237
Science. 1999 Apr 16;284(5413):489-93
10205057
Science. 1986 Jan 24;231(4736):397-400
2934816
Curr Pharm Des. 2006;12(36):4751-70
17168776
J Orthop Res. 2004 Jul;22(4):901-9
15183453